

April 1, 2024  
Web Announcement 3320

## Drug Use Review (DUR) Board Approves Changes Effective April 1, 2024

The Nevada Medicaid Drug Use Review (DUR) Board met on January 18, 2024, and voted to adopt the following changes effective April 1, 2024:

Drug Class/Program	Changes
Saphnelo® (anifrolumab-fnia)	Addition of new clinical criteria
Tavneos® (avacopan)	Addition of new clinical criteria
Uplizna® (inebilizumab-cdon)	Addition of new clinical criteria
Voxzogo® (vosoritide)	Addition of new clinical criteria
Narcolepsy agents	Updates to existing criteria
Anti-Hepatitis Agents	Updates to existing criteria
Incretin Mimetics	Updates to existing criteria

Prior Authorization forms may be found on the pharmacy webpage:  
<https://nevadamedicaid.magellanrx.com/provider/forms> (pharmacy/point-of-sale)